[26 April 2018]
Funding will support studies on new treatments for neonatal sepsis and drug-resistant STIs in South Africa
The Global Antibiotic Research and Development Partnership (GARDP) is pleased to announce the strengthening of its collaborative efforts with the South African Medical Research Council (SAMRC). SAMRC has provided 4 million Rand towards furthering GARDP’s activities in South Africa. This funding will contribute to the global development and delivery of affordable new or improved antibiotic treatments for drug-resistant bacterial infections where there are currently no adequate treatments, beginning with neonatal sepsis and sexually transmitted infections (STIs).
Antimicrobial resistance (AMR) is a global concern and an important public health priority for South Africa. Neonatal sepsis accounts for some 214,000 deaths per year globally, and the incidence of drug-resistant STIs such as gonorrhoea is also on the increase. GARDP focuses its research and development efforts towards meeting priority infectious diseases that threaten public health. SAMRC’s funding will be directed towards supporting clinical studies in neonatal sepsis and STIs across several research sites in South Africa.
‘We are grateful for South African Medical Research Council’s continued support in our efforts to boost the development of new antibiotics. Our work is global in focus and therefore reflects the needs of developing countries,’ said Dr Manica Balasegaram, Director of GARDP. ‘This funding will contribute to our ambition to develop two new treatments for neonatal sepsis, as well as register a new treatment for gonorrhoea in a number of countries, including South Africa.’
‘We are pleased to collaborate with GARDP in its efforts to develop new antibiotic treatments. AMR is a global concern and an important public health issue in South Africa,’ said Professor Glenda Gray, President of SAMRC. ‘GARDP’s projects on neonatal sepsis and STIs will go a long way in identifying challenges and priorities, raising awareness and informing interventions in the fight against AMR.’
‘Collaborations such as these are important if we are to tackle antimicrobial resistance. Neonatal sepsis is of growing concern in South Africa, and it is now a major barrier to achieving the sustainable development goal to reduce neonatal mortality,’ said Carol Ruffell, head of the joint office of the Drugs for Neglected Diseases initiative (DNDi) and GARDP in South Africa. ‘Similarly, while the impact of gonorrhoea is truly global, Africa and Western Pacific regions have the highest incidence levels of this sexually-transmitted infection.’
GARDP was established as a joint initiative by the World Health Organization (WHO) and the Drugs for Neglected Disease initiative (DNDi) in 2016. GARDP is an important element of WHO’s Global Action Plan on antimicrobial resistance that calls for new public-private partnerships to encourage R&D of new antimicrobial agents and diagnostics.
SAMRC’s mandate is to improve the health of South Africans through research, development and technology transfer, so that people can enjoy a better quality of life. It aims to help strengthen the health systems throughout South Africa and has been one of the first institutions globally to provide financial support to GARDP since its creation. Read their press release here.
Tel: +41 22 907 76 28
Mob: +41 79 640 00 99